These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18006912)

  • 1. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
    Setiawan VW; Schumacher FR; Haiman CA; Stram DO; Albanes D; Altshuler D; Berglund G; Buring J; Calle EE; Clavel-Chapelon F; Cox DG; Gaziano JM; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn J; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Ma J; Le Marchand L; Linseisen J; Lund E; Navarro C; Overvad K; Palli D; Peeters PH; Pike MC; Riboli E; Stampfer MJ; Thun MJ; Travis R; Trichopoulos D; Yeager M; Ziegler RG; Spencer Feigelson H; Chanock SJ
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2237-46. PubMed ID: 18006912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.
    Travis RC; Schumacher F; Hirschhorn JN; Kraft P; Allen NE; Albanes D; Berglund G; Berndt SI; Boeing H; Bueno-de-Mesquita HB; Calle EE; Chanock S; Dunning AM; Hayes R; Feigelson HS; Gaziano JM; Giovannucci E; Haiman CA; Henderson BE; Kaaks R; Kolonel LN; Ma J; Rodriguez L; Riboli E; Stampfer M; Stram DO; Thun MJ; Tjønneland A; Trichopoulos D; Vineis P; Virtamo J; Le Marchand L; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2734-44. PubMed ID: 19789370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).
    Dossus L; Kaaks R; Canzian F; Albanes D; Berndt SI; Boeing H; Buring J; Chanock SJ; Clavel-Chapelon F; Feigelson HS; Gaziano JM; Giovannucci E; Gonzalez C; Haiman CA; Hallmans G; Hankinson SE; Hayes RB; Henderson BE; Hoover RN; Hunter DJ; Khaw KT; Kolonel LN; Kraft P; Ma J; Le Marchand L; Lund E; Peeters PH; Stampfer M; Stram DO; Thomas G; Thun MJ; Tjonneland A; Trichopoulos D; Tumino R; Riboli E; Virtamo J; Weinstein SJ; Yeager M; Ziegler RG; Cox DG
    Carcinogenesis; 2010 Mar; 31(3):455-61. PubMed ID: 19965896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium.
    Canzian F; Cox DG; Setiawan VW; Stram DO; Ziegler RG; Dossus L; Beckmann L; Blanché H; Barricarte A; Berg CD; Bingham S; Buring J; Buys SS; Calle EE; Chanock SJ; Clavel-Chapelon F; DeLancey JO; Diver WR; Dorronsoro M; Haiman CA; Hallmans G; Hankinson SE; Hunter DJ; Hüsing A; Isaacs C; Khaw KT; Kolonel LN; Kraft P; Le Marchand L; Lund E; Overvad K; Panico S; Peeters PH; Pollak M; Thun MJ; Tjønneland A; Trichopoulos D; Tumino R; Yeager M; Hoover RN; Riboli E; Thomas G; Henderson BE; Kaaks R; Feigelson HS
    Hum Mol Genet; 2010 Oct; 19(19):3873-84. PubMed ID: 20634197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
    Chen YC; Kraft P; Bretsky P; Ketkar S; Hunter DJ; Albanes D; Altshuler D; Andriole G; Berg CD; Boeing H; Burtt N; Bueno-de-Mesquita B; Cann H; Canzian F; Chanock S; Dunning A; Feigelson HS; Freedman M; Gaziano JM; Giovannucci E; Sánchez MJ; Haiman CA; Hallmans G; Hayes RB; Henderson BE; Hirschhorn J; Kaaks R; Key TJ; Kolonel LN; LeMarchand L; Ma J; Overvad K; Palli D; Pharaoh P; Pike M; Riboli E; Rodriguez C; Setiawan VW; Stampfer M; Stram DO; Thomas G; Thun MJ; Travis RC; Virtamo J; Trichopoulou A; Wacholder S; Weinstein SJ
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1973-81. PubMed ID: 17932344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation in CYP17 and endometrial cancer risk.
    Gaudet MM; Lacey JV; Lissowska J; Peplonska B; Brinton LA; Chanock S; Garcia-Closas M
    Hum Genet; 2008 Mar; 123(2):155-62. PubMed ID: 18172694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
    Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
    Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
    Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
    Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.
    Cheng I; Penney KL; Stram DO; Le Marchand L; Giorgi E; Haiman CA; Kolonel LN; Pike M; Hirschhorn J; Henderson BE; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1993-7. PubMed ID: 17035411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
    Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
    Cai L; Huang W; Chou KC
    Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.
    Zhang L; Gu L; Qian B; Hao X; Zhang W; Wei Q; Chen K
    Breast Cancer Res Treat; 2009 Mar; 114(2):327-38. PubMed ID: 18629629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.
    Haiman CA; Stram DO; Cheng I; Giorgi EE; Pooler L; Penney K; Le Marchand L; Henderson BE; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1021-5. PubMed ID: 16702386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms associated with circulating sex hormone levels in postmenopausal women.
    Dunning AM; Dowsett M; Healey CS; Tee L; Luben RN; Folkerd E; Novik KL; Kelemen L; Ogata S; Pharoah PD; Easton DF; Day NE; Ponder BA
    J Natl Cancer Inst; 2004 Jun; 96(12):936-45. PubMed ID: 15199113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans.
    Kittles RA; Panguluri RK; Chen W; Massac A; Ahaghotu C; Jackson A; Ukoli F; Adams-Campbell L; Isaacs W; Dunston GM
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):943-7. PubMed ID: 11535545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of the association between CYP17 rs743572 polymorphism and prostate cancer risk.
    Wang Y; Zhang Y; Meng H; Hou X; Li Z; Liu Q; Meng L
    Cell Biochem Biophys; 2015 Mar; 71(2):983-91. PubMed ID: 25323563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP17 gene polymorphism in relation to breast cancer risk: a case-control study.
    Einarsdóttir K; Rylander-Rudqvist T; Humphreys K; Ahlberg S; Jonasdottir G; Weiderpass E; Chia KS; Ingelman-Sundberg M; Persson I; Liu J; Hall P; Wedrén S
    Breast Cancer Res; 2005; 7(6):R890-6. PubMed ID: 16280037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects.
    Yao L; Fang F; Wu Q; Yang Z; Zhong Y; Yu L
    Breast Cancer Res Treat; 2010 Jul; 122(1):221-7. PubMed ID: 20013047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary isoflavone intake, polymorphisms in the CYP17, CYP19, 17beta-HSD1, and SHBG genes, and risk of breast cancer in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.
    Iwasaki M; Hamada GS; Nishimoto IN; Netto MM; Motola J; Laginha FM; Kasuga Y; Yokoyama S; Onuma H; Nishimura H; Kusama R; Kobayashi M; Ishihara J; Yamamoto S; Hanaoka T; Tsugane S
    Nutr Cancer; 2010; 62(4):466-75. PubMed ID: 20432167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.